Reported Sunday, IDEAYA Biosciences Announces Updated Darovasertib Topline Results Guidance From Phase 2/3 OptimUM-02 Trial In First-Line Metastatic Uveal Melanoma, Database Lock Due First Half April

Benzinga Newsdesk www.benzinga.com Neutral 90.5%

Neg 0% Neu 90.5% Pos 0%

Comments

No comments yet. Be the first!